Back to search
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-small-Cell Lung
Clinicaltrials.gov:
EU CTIS:
#2023-505065-91-00
EudraCT:
J&J ID:
#CR109264
Other:
#61186372NSC2002
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Carcinoma, Non-small-Cell Lung
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
Amivantamab
Carboplatin
Direct Oral Anticoagulant (DOAC)
Lazertinib
Low Molecular Weight Heparin (LMWH)
Pemetrexed
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
November 11, 2022
Trial end date
August 18, 2028
CT.gov ID
#NCT05498428
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Brazil,
- China,
- France,
- Germany,
- Israel,
- Italy,
- Japan,
- Malaysia,
- South Korea,
- Spain,
- United Kingdom,
- United States
Loading...
Enrolling
Milan, Italy, 20162
Enrolling
Orlando, Florida, United States, 32804
Enrolling
Porto Alegre, Brazil, 90035-001
Enrolling
Monza, Italy, 20090
Enrolling
Naples, Italy, 80131
Enrolling
Petaling Jaya, Malaysia, 46050
Enrolling
Boston, Massachusetts, United States, 02118
Enrolling
Caen, France, 14076
Enrolling
Edinburgh, United Kingdom, EH4 2XU
Enrolling
Shanghai, China, 200032
Enrolling
São Paulo, Brazil, 01509 900
Enrolling
Barretos, Brazil, 14784-400
Enrolling
Alicante, Spain, 03010
Enrolling
Villejuif, France, 94800
Enrolling
Hackensack, New Jersey, United States, 07601
Enrolling
Harbin, China, 150000
Enrolling
Málaga, Spain, 29010
Enrolling
A Coruña, Spain, 15006
Enrolling
Barcelona, Spain, 08035
Enrolling
Valencia, Spain, 46010
Enrolling
Barcelona, Spain, 08003
Enrolling
Madrid, Spain, 28007
Enrolling
Valencia, Spain, 46014
Enrolling
Madrid, Spain, 28041
Enrolling
Madrid, Spain, 28046
Enrolling
Madrid, Spain, 28034
Enrolling
Seville, Spain, 41009
Enrolling
Barcelona, Spain, 08025
Enrolling
São Paulo, Brazil, 01327 001
Enrolling
Kuantan, Malaysia, 25100
Enrolling
Kuching, Malaysia, 93586
Enrolling
Huizhou, China, 516001
Enrolling
Barcelona, Spain, 8908
Enrolling
Paris, France, 75248
Enrolling
Nîmes, France, 30029
Enrolling
Saint-Herblain, France, 44805
Enrolling
Rio de Janeiro, Brazil, 22281 100
Enrolling
Salvador, Brazil, 41253-190
Enrolling
Londrina, Brazil, 86015
Enrolling
Changchun, China, 130000
Enrolling
Washington D.C., District of Columbia, United States, 20016
Enrolling
Würzburg, Germany, 97074
Enrolling
Leicester, United Kingdom, LE1 5WW
Enrolling
Grosshandorf, Germany, 22927
Enrolling
Immenhausen, Germany, 34376
Enrolling
Miami Beach, Florida, United States, 33140
Enrolling
Goyang-si, South Korea, 10408
Enrolling
Nottingham, United Kingdom, NG5 1PB
Enrolling
Milan, Italy, 20132
Enrolling
Belo Horizonte, Brazil, 30130 090
Enrolling
Genova, Italy, 16132
Enrolling
Portsmouth, United Kingdom, PO6 3LY
Enrolling
Petah Tikva, Israel, 4941492
Enrolling
Haifa, Israel, 3109601
Enrolling
New Brunswick, New Jersey, United States, 08901
Enrolling
Seongnam-si, South Korea, 13620
Enrolling
Seoul, South Korea, 03080
Enrolling
Seoul, South Korea, 03722
Enrolling
Jerusalem, Israel, 9103102
Enrolling
Ramat Gan, Israel, 52621
Enrolling
Chengdu, China, 610041
Enrolling
Baltimore, Maryland, United States, 21224
Enrolling
Hangzhou, China, 310016
Enrolling
Stanford, California, United States, 94305
Enrolling
Seattle, Washington, United States, 98104
Enrolling
Guangzhou, China, 510060
Enrolling
Hangzhou, China, 310003
Enrolling
Chongqing, China, 400038
Enrolling
Wenzhou, China, 325000
Enrolling
Xi'an, China, 710061
Enrolling
Tianjin, China, 300052
Enrolling
Devon, United Kingdom, TQ2 7AA
Enrolling
Wuhan, China, 430022
Enrolling
Cologne, Germany, 50937
Enrolling
London, United Kingdom, NW1 2PG
Enrolling
Kuala Lumpur, Malaysia, 59100
Enrolling
Orange, California, United States, 92868
Enrolling
La Jolla, California, United States, 92093
Enrolling
Westwood, Kansas, United States, 66205
Enrolling
Fairfax, Virginia, United States, 22031
Enrolling
St Louis, Missouri, United States, 63110
Enrolling
Chengdu, China, 610047
Enrollment complete
Himeji, Japan, 670-8520
Enrollment complete
Niigata, Japan, 951-8566
Enrollment complete
Matsusaka, Japan, 515 8544
Enrollment complete
Shizuoka, Japan, 411 8777
Enrollment complete
Tokyo, Japan, 135 8550
Enrollment complete
Wakayama, Japan, 641 8510
Completed
Baoding, China, 071051
Completed
Seoul, South Korea, 05505
Completed
Boca Raton, Florida, United States, 33486
Completed
Dijon, France, 21079
Completed
Cheltenham, United Kingdom, GL53 7AN
Completed
Cleveland, Ohio, United States, 44195
Completed
Cleveland, Ohio, United States, 44111
Completed
Mayfield Heights, Ohio, United States, 44124
Completed
Warrensville Heights, Ohio, United States, 44122
Completed
Berlin, Germany, 13125
Completed
Tampa, Florida, United States, 33612
Completed
East Syracuse, New York, United States, 13057
Completed
Wuxi, China, 214122
Completed
São Paulo, Brazil, 01409-001
Completed
Liuzhou, China, 545006
Completed
Kfar Saba, Israel, 44281
Completed
Winston-Salem, North Carolina, United States, 27106
Completed
Charlotte, North Carolina, United States, 28204
Completed
Everett, Washington, United States, 98201
Completed
Salt Lake City, Utah, United States, 84112
Completed
Seattle, Washington, United States, 98101
Completed
Yantai, China, 264000
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
